Part, Chapter, Paragraph
1 II, 5. 2. 3| to improvements in modern therapies for acute phase of myocardial
2 II, 5. 2. 3| infarction, such as thrombolytic therapies, PCI and CABG, and in more
3 II, 5. 2. 3| CABG, and in more efficient therapies for chronic conditions and
4 II, 5. 2. 4| demonstrated the efficacy of therapies, recommendations on management
5 II, 5. 5.Int| attempted suicide. Behavioural therapies have shown encouraging results
6 II, 5. 5. 3| Five disease-modifying therapies for the initial management
7 II, 5. 5. 3| relation to treatments, therapies and services, research,
8 II, 5. 5. 3| and access to treatment, therapies and services in the management
9 II, 5. 5. 3| application of immunoprophylatic therapies.~· Recommendations on Rehabilitation
10 II, 5. 5. 3| their illness.~· Symptomatic Therapies Consensus Paper based on
11 II, 5. 5. 3| review of MS treatments and therapies, reviewing the social support
12 II, 5. 5. 3| since the advent of newer therapies (Eichhorn and Oertel, 1994).
13 II, 5. 6. 3| be reduced with current therapies. Modern treatment is effective
14 II, 5. 15. 3| economic burden of these new therapies (Drummond et al, 2007; Dear
15 II, 5. 15. 4| gene, cell and tissue-based therapies development and will set
16 II, 6. 3. 3| antiretroviral combination therapies introduced in the mid-1990s
17 II, 9 | in men. For some of these therapies, the evidence derives largely
18 II, 9 | prevention trials; in general, therapies that work in secondary prevention
19 II, 9. 3. 1| The effect of menopausal therapies on the risk for cancer is
20 II, 9. 3. 1| available pharmacologic therapies for menopausal women and
21 II, 9. 3. 1| supplementation and pharmacologic therapies for osteoporosis may yield
22 II, 9. 3. 1| in men. For some of these therapies, the evidence derives largely
23 II, 9. 3. 1| prevention trials; in general, therapies that work in secondary prevention
24 II, 9. 4. 5| care providers. Surveys of therapies and the inclusion of older
25 II, 9. 5. 4| hypothesis, diagnostic tools, therapies, prevention rehabilitation
26 III, 10. 2. 1| pharmacological and behavioural therapies significantly increase the
27 III, 10. 2. 4| well as with response to therapies;~· the differentiation between
28 IV, 11. 4 | non-pharmacological interventions and therapies, surgery and rehabilitation.
29 IV, 11. 5. 1| the indications of these therapies. The use of human organs
30 IV, 11. 5. 5| and solid organ transplant therapies,~2. new cell therapies for
31 IV, 11. 5. 5| transplant therapies,~2. new cell therapies for CSE and solid organ
32 IV, 11. 5. 6| indicators than other replacement therapies. Results of organ transplantation
33 IV, 12. 10 | Nicotine Replacement Therapies made available free of charge
